From 2022 to 2028, the global seasonal affective disorder therapeutics market is slated to rise at a CAGR of 4.3%. Currently, the market accounts for a valuation of USD 848.2 Million, and is projected to close in on USD 1.1 Billion by the end of 2028.
| Attribute | Details |
|---|---|
| Seasonal Affective Disorder Therapeutics Market Size (2022) | USD 848.2 Million |
| Projected Market Value (2028) | USD 1.1 Billion |
| Global Market Growth Rate (2022 to 2028) | 4.3% CAGR |
| North America Market Share | 38.4% |
Sales of seasonal affective disorder therapeutic drugs and devices account for a share of 4.6% in the global depressive disorder treatment market. Preference and popularity of bright light therapy among physicians and patients is expected to be a major trend driving seasonal affective disorder therapeutics demand growth through 2028.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 4.29% |
| H1, 2022 Projected | 4.34% |
| H1, 2022 Outlook | 4.24% |
| BPS Change - H1, 2022 (O) – H1, 2022 (P) | (-) 10 ↓ |
| BPS Change – H1, 2022 (O) – H1, 2021 | (-) 05 ↓ |
The market for seasonal affective disorder therapeutics is subject to change as per the regulatory dynamics for drugs, in accordance to macroeconomic and industrial standards.
The variation between the BPS values observed within this market in H1, 2022 - outlook over H1, 2022 projected reflects a decline of 10 BPS units. Additionally, a drop in BPS growth in H1-2022 over H1-2021 by 05 Basis Point Share (BPS) is demonstrated by the market.
The decline in the BPS values is associated with the limited evidence for the effectiveness of light therapy when compared with other available preventive options. Moreover, patient preference towards treatment modalities is dominant for the preventive treatment of seasonal affective disorder.
On the contrary, the market is expected to gain traction in terms of growth and sales outlook during the forecast period. This is supported with the development of second-generation antidepressants for the treatment of seasonal affective disorder in adults.
The key developments in the market include the FDA approval of an extended-release antidepressant, bupropion, for the prevention of recurrent seasonal affective disorder with major depressive episodes.
Anxiety and depression among the general population have seen a substantial spike over the past few years and this has majorly influenced the healthcare industry in multiple ways. The seasonal affective disorder therapeutics market exhibited expansion at a CAGR of 3.7% from 2013 to 2021.
Increasing prevalence of seasonal affective disorders, rising instances of depression among the general population, increasing availability of treatment options, and rising research and development activities in therapeutics are some major factors that are anticipated to influence seasonal affective disorder therapeutics demand over the forecast period.
Research & development activities are of paramount importance in helping create effective therapeutic solutions for seasonal affective disorders. Seasonal affective disorder therapeutic providers are focusing on expanding their research scope and creating novel therapeutic solutions for patients.
Demand for seasonal affective disorder therapeutics is estimated to rise at a CAGR of 4.3% from 2022 to 2028.
Principal Consultant
Increasing Popularity of Light Therapy to Positively Impact Market Potential
Bright light therapy has emerged as one of the most popular aspects of the seasonal affective disorder therapeutics marketplace in recent years. This therapy provides a rapid anti-depressant effect on patients and has seen an increase in recommendation by physicians and health professionals.
Lack of Research Data & Adverse Effects of Anti-depressants to Majorly Hamper Market Growth
Scarce research data and low availability of information on seasonal affective disorders are anticipated to be major barriers for seasonal affective disorder therapeutics providers. Inadequate research data on effects of bright light and blue light on the treatment of patients is expected to restrain market potential.
Adverse effects associated with excessive use of anti-depressants and other therapy drugs are predicted to be a major issue in the seasonal affective disorder therapeutics industry landscape over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Statistical analysis of seasonal affective disorder therapeutics market metrics for regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA) has been assessed in this market study.
Accounting for a dominative market share of 38.4% in the global seasonal affective disorder therapeutics marketplace, North America is anticipated to provide a highly beneficial setting for seasonal affective disorder therapeutic companies. Increasing prevalence of seasonal affective disorders and rising focus on healthcare are expected to be major trends in this region.
Second to North America, the Europe seasonal affective disorder therapeutics product market accounts for a market share of 29.5% in 2022. Increasing healthcare expenditure and rising research and development activities for seasonal affective disorders are expected to be prominent trends in this region through 2028.
Rising awareness about anxiety and depression is expected to majorly boost awareness about seasonal affective disorders in regions of East Asia and South Asia. Currently, East Asia and South Asia account for market shares of 18.5% and 7.5% in the global seasonal affective disorder therapeutics market.
Lack of awareness, low research activity, and underdeveloped healthcare infrastructure are expected to lead to slow growth in seasonal affective disorder therapeutics demand in regions of Oceania and the MEA. At present, the MEA and Oceania regions hold market shares of 1.5% and 1%, respectively, in the global seasonal affective disorder therapeutics industry.
Rising Awareness & Focus on Mental Health Expected to Positively Impact Market Expansion
Mental health has emerged as one of the most concerning healthcare issues in India over the past few years and this has also bolstered demand for multiple seasonal affective disorder treatments. Developing healthcare infrastructure, lack of awareness, and lack of availability of treatments are expected to be prominent trends controlling demand for seasonal affective disorder therapeutics in India.
High Prevalence of Multiple Seasonal Affective Disorders to Positively Influence Demand
The USA has seen a substantial increase in instances of anxiety and depression-related disorders and this has fostered a demand for seasonal affective disorder therapeutics. Rising instances of bipolar disorders is the major trend that drives the market potential for this nation.
High research & development activities and increasing availability of treatment options are also expected to favor seasonal affective disorder therapeutics demand.
Seasonal affective disorder therapeutic providers are focusing on developing and launching novel treatment solutions to maximize their revenue potential in the nation.
High Incidence of Bipolar Disorders to Majorly Govern Seasonal Affective Disorder Therapeutics Demand
Bipolar disorder has emerged as one of the most prominent seasonal affective disorders over recent years and this has led to its substantial influence on the seasonal affective disorder therapeutics marketplace.
This disorder is expected to hold a dominant market share over the forecast period and is expected to be a majorly influential segment through 2028.
Seasonal affective disorder therapeutic providers are investing in the research & development of novel therapeutics specific to seasonal affective disorders. Seasonal affective disorder therapeutic equipment manufacturing companies are also adopting organic and inorganic strategies to increase awareness about seasonal affective disorders and boost their sales revenue.
As it is the first FDA-approved drug of its kind, it is expected to see high demand over the coming years.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Turkey, South Africa, and GCC Countries |
| Key Market Segments Covered | Treatment Type, Disorder Type, Distribution Channel, Region |
| Key Companies Profiled | Allergan plc.; Eli Lily Company; GlaxoSmithKline; Pfizer Inc.; Teva Pharmaceuticals; Bausch Health Companies Inc.; F. Hoffman-La Roche AG; Mylan N.V.; Sanofi AG; Novartis AG; Janssen Pharmaceuticals Inc.; Koninklije Philips N.V.; The Sunbox Company; Beurer GmbH; Lucimed S.A. |
| Pricing | Available upon Request |
The global seasonal affective disorder therapeutics market is anticipated to attain a valuation of USD 1.1 Billion by the end of 2028.
Key suppliers of seasonal affective disorder therapeutic systems are F. Hoffman-La Roche AG, Mylan N.V., Sanofi AG, Novartis AG, Janssen Pharmaceuticals Inc., Koninklije Philips N.V., and The Sunbox Company.
Currently, the North America seasonal affective disorder therapeutics market holds a prominent share of 38.4% in the global industry.
From 2022 to 2028, the seasonal affective disorder therapeutics market is predicted to expand at a CAGR of 4.3%.
In 2022, the seasonal affective disorder therapeutics market accounts for a value of USD 848.2 Million.
1. Executive Summary 2. Market Overview 3. Market Background 4. Key Success Factors 5. Global Seasonal Affective Disorder Therapeutics Market Volume Analysis 2013 to 2021 and Forecast, 2022 to 2028 6. Global Seasonal Affective Disorder Therapeutics Market to Pricing Analysis 7. Global Seasonal Affective Disorder Therapeutics Market Value Analysis 2013 to 2021 and Forecast, 2022 to 2028 8. Global Seasonal Affective Disorder Therapeutics Market Analysis 2013 to 2021 and Forecast 2022 to 2028, by Treatment Type 8.1. Drugs 8.1.1. Selective serotonin reuptake inhibitors (SSRIs) 8.1.2. Norepinephrine to dopamine reuptake inhibitor (NDRI) 8.1.3. Serotonin and norepinephrine reuptake inhibitors (SNRIs) 8.1.4. Monoamine oxidase inhibitors (MAOIs) 8.1.5. Tricyclic antidepressants (TCAs) 8.2. Devices 8.2.1. Light Boxes 8.2.2. Dawn Stimulators 8.2.3. Desk Lamps 8.2.4. Sun Visors 9. Global Seasonal Affective Disorder Therapeutics Market Analysis 2013 to 2021 and Forecast 2022 to 2028, by Disorder Type 9.1. Fall to winter onset 9.1.1. Spring to summer onset 9.1.2. Unipolar Disorder 9.2. Bipolar Disorder 10. Global Seasonal Affective Disorder Therapeutics Market Analysis 2013 to 2021 and Forecast 2022 to 2028, by Distribution Channel 10.1. Institutional Sales 10.1.1. Hospitals 10.1.2. Clinics 10.1.3. Wellness Centers & Spas 10.2. Retail Sales 10.2.1. Retail Pharmacies 10.2.2. Drug Stores 10.2.3. Online Sales 11. Global Seasonal Affective Disorder Therapeutics Market Analysis 2013 to 2021 and Forecast 2022 to 2028, by Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. Middle East and Africa (MEA) 11.5. East Asia 11.6. South Asia 11.7. Oceania 12. North America Seasonal Affective Disorder Therapeutics Market Analysis 2013 to 2021 and Forecast 2022 to 2028 13. Latin America Seasonal Affective Disorder Therapeutics Market Analysis 2013 to 2021 and Forecast 2022 to 2028 14. Europe Seasonal Affective Disorder Therapeutics Market Analysis 2013 to 2021 and Forecast 2022 to 2028 15. South Asia Seasonal Affective Disorder Therapeutics Market Analysis 2013 to 2021 and Forecast 2022 to 2028 16. East Asia Seasonal Affective Disorder Therapeutics Market Analysis 2013 to 2021 and Forecast 2022 to 2028 17. Oceania Seasonal Affective Disorder Therapeutics Market Analysis 2013 to 2021 and Forecast 2022 to 2028 18. Middle East and Africa Seasonal Affective Disorder Therapeutics Market Analysis 2013 to 2021 and Forecast 2022 to 2028 19. Emerging Countries Seasonal Affective Disorder Therapeutics Market Analysis 2013 to 2021 and Forecast 2022 to 2028 20. Competition Analysis 20.1. Allergan plc 20.2. Eli Lily Company 20.3. GlaxoSmithKline 20.4. Pfizer Inc. 20.5. Teva Pharmaceuticals 20.6. Bausch Health Companies Inc. 20.7. F. Hoffmann to La Roche AG 20.8. Mylan N.V. 20.9. Novartis AG 20.10. Janssen Pharmaceuticals, Inc. 20.11. Koninklijke Philips N.V 20.12. The Sunbox Company 20.13. Beurer GmbH 20.14. Lucimed S.A. 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Seasonal Affective Disorder Therapeutics Market
